Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048554 · ClinicalTrials.gov registry record · Phase 2
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
A Phase 2 study, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01048554: Completed Phase 2 study, sponsored by Mt. Sinai Medical Center, Miami.
NCT01048554 is a Phase 2 study that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01048554, a Phase 2 study, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This research is being done because melanoma in the brain is very difficult to treat because it does not respond to radiation or to chemotherapy, such as temozolomide. One of the reasons for this is that the melanoma can make chemicals that signal the brain to provide new blood vessels for the tumor. The main signal is called VEGF. Bevacizumab is an antibody that blocks VEGF. The investigators want to see if the combination of bevacizumab and temozolomide will stop the melanoma from growing.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
What the finished NCT01048554 record still lists
NCT01048554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01048554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01048554 about?
NCT01048554 is a clinical study titled "Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System". This research is being done because melanoma in the brain is very difficult to treat because it does not respond to radiation or to chemotherapy, such as temozolomide. One of the reasons for this is that the melanoma can make chemicals that signal the brain to provide new blood vessels for the tumor...
What is the current status of trial NCT01048554?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01048554?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT01048554?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01048554's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia